BioSpace News Archive

Year

• 2005
• 2006
• 2007
• 2008
• 2009
• 2010
• 2011
• 2012
• 2013
• 2014
• 2015
• 2016
• 2017
• 2018
• 2019
• 2020
• 2021
• 2022
• 2023
• 2024
• 2025
• 2026

Month

• January
• February
• March
• April
• May
• June
• July
• August
• September

Day

• 1
• 2
• 3
• 4
• 5
• 6
• 9
• 10
• 11
• 12
• 13
• 15
• 16
• 17
• 18
• 19
• 20
• 22
• 23
• 24
• 25
• 26
• 27
• 30
• 31

• Press Releases

  DBV Technologies Highlights Additional Data from Successful Phase 3 VITESSE Study at the AAAAI 2026 Annual Meeting

  March 2, 2026

   · 

  8 min read
• Press Releases

  Septerna Announces Positive Phase 1 Data for SEP-631, an Oral MRGPRX2 NAM for the Treatment of Mast Cell-Driven Diseases, and Outlines Initial Phase 2 Development Strategy

  March 2, 2026

   · 

  8 min read
• Press Releases

  Upstream Bio Presents Additional Analyses from the Phase 2 VIBRANT Trial of Verekitug in Chronic Rhinosinusitis with Nasal Polyps at 2026 AAAAI Annual Meeting

  March 2, 2026

   · 

  10 min read
• Press Releases

  Celldex Presents Positive Data Demonstrating Barzolvolimab Retreatment Achieves Similar Profound Efficacy to First Exposure in Patients with Cold Urticaria (ColdU) and Symptomatic Dermographism (SD) Further Demonstrating First-in-Class and Best-in-Disease Barzolvolimab Profile at AAAAI 2026

  March 2, 2026

   · 

  7 min read
• Press Releases

  Rhythm Pharmaceuticals Announces Additional Positive Data from Phase 3 TRANSCEND trial of Setmelanotide in Patients with Acquired Hypothalamic Obesity

  March 2, 2026

   · 

  10 min read
• Press Releases

  Investor Education Webinar

  March 2, 2026

   · 

  6 min read
• Press Releases

  Model Medicines to Highlight Two IND-Track Assets, Record-Setting AI Platform at BIO Investment & Growth Summit 2026

  Company to spotlight its two lead drug candidates, MDL-001, a novel direct-acting antiviral targeting RdRp-Thumb 1, and MDL-4102, a novel transcriptional regulator targeting BRD4, both advancing toward IND.

  March 2, 2026

   · 

  1 min read
• Press Releases

  Otsuka Medical Devices/Otsuka Pharmaceutical: Paradise Ultrasound Renal Denervation System for the Treatment of Resistant Hypertension, Now Covered by Insurance and Commercially Available in Japan

  March 2, 2026

   · 

  3 min read
• Press Releases

  Jaypirca® (Pirtobrutinib) Approved in China for the Treatment of Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

  March 2, 2026

   · 

  9 min read
• Press Releases

  XPOVIO® Receives Reimbursement Approval in South Korea for a Second Multiple Myeloma Indication

  March 2, 2026

   · 

  4 min read